← Back to Search

CAR T-cell Therapy

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1
Waitlist Available
Research Sponsored by Tceleron Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 15 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new treatment where a patient's immune cells are modified to better attack advanced prostate cancer. It targets patients whose cancer has spread and doesn't respond to usual treatments. The modified cells are trained to find and kill cancer cells by recognizing a specific marker on them.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 15 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 15 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cohort Expansion: Safety of CART-PSMA-TGFβRDN
Dose Escalation: Dose Identification of CART-PSMA-TGFβRDN
Secondary study objectives
Feasibility of CART-PSMA-TGFβRDN
Peripheral expansion and persistence of CART-PSMA-TGFβRDN
Preliminary efficacy of CART-PSMA-TGFβRDN as assessed by biochemical Objective Response Rate (ORR)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dose EscalationExperimental Treatment4 Interventions
Dose escalation of intravenous CART-PSMA-TGFβRDN cells for patients with metastatic castration resistant prostate cancer
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
2010
Completed Phase 4
~2310
Fludarabine
2012
Completed Phase 4
~1860
Anakinra
2016
Completed Phase 4
~1320

Find a Location

Who is running the clinical trial?

Tceleron Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
19 Total Patients Enrolled
Tmunity TherapeuticsLead Sponsor
6 Previous Clinical Trials
122 Total Patients Enrolled
~3 spots leftby Dec 2025